Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases Data Centre, Rome, Italy.
Blood Adv. 2023 Nov 28;7(22):7045-7055. doi: 10.1182/bloodadvances.2023010841.
Hodgkin lymphoma (HL) has become 1 of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support informed clinical decisions. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group previously developed the EORTC Quality of Life Questionnaire (QLQ) Hodgkin Lymphoma 27. This paper reports the final results of an international study by the EORTC group to develop a HRQoL disease-specific measure for these patients: the EORTC QLQ-HL27. Patients with a confirmed diagnosis of HL (N = 381) were enrolled from 12 countries and completed the EORTC QLQ-C30, QLQ-HL27, and a debriefing questionnaire at baseline (any time after diagnosis). A subset completed a retest (n = 126) or responsiveness-to-change analyses (RCA) second measurement (n = 98). Psychometrics were evaluated. Confirmatory factor analysis showed an acceptable fit of the 27 items of the QLQ-HL27 on its 4 scales (symptom burden, physical condition/fatigue, emotional impact, and worries about health/functioning). Test-retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results. Symptom burden and fatigue was higher among patients on treatment (with 36%-83% reporting at least a few problems) compared with those who had completed treatment (19%-61% reporting at least a few problems). Prevalence of worries about health and functioning (reporting at least some worry) was similar for patients on treatment (51%-81%) vs those who had completed treatment (52%-78%). Implementation of the EORTC QLQ-HL27 in research and clinical applications will increase sensitivity of HRQoL assessment in patients with HL. High quality data generated through use of this questionnaire are expected to facilitate clinical decision making in the HL setting.
霍奇金淋巴瘤（HL）已成为最可治愈的癌症之一。因此，严格评估这些患者的健康相关生活质量（HRQoL）和症状负担对于支持明智的临床决策至关重要。欧洲癌症研究与治疗组织（EORTC）质量保证组先前开发了 EORTC 生活质量问卷（QLQ）霍奇金淋巴瘤 27 项。本文报告了 EORTC 小组进行的一项国际研究的最终结果，该研究旨在为这些患者开发一种 HRQoL 疾病特异性衡量标准：EORTC QLQ-HL27。来自 12 个国家的 381 名确诊为 HL 的患者参加了该研究，并在基线时（确诊后任何时间）完成了 EORTC QLQ-C30、QLQ-HL27 和一份情况介绍问卷。一部分患者完成了重测（n=126）或反应性变化分析（RCA）的第二次测量（n=98）。评估了心理测量学。验证性因子分析表明，QLQ-HL27 的 27 个项目在其 4 个量表（症状负担、身体状况/疲劳、情绪影响和对健康/功能的担忧）上具有可接受的拟合度。重测信度、收敛效度、已知组比较和 RCA 均得出令人满意的结果。与已完成治疗的患者（19%-61%报告至少存在一些问题）相比，正在接受治疗的患者（36%-83%报告至少存在一些问题）的症状负担和疲劳问题更高。对健康和功能的担忧（报告至少存在一些担忧）的发生率在接受治疗的患者（51%-81%）与已完成治疗的患者（52%-78%）中相似。在 HL 患者中，实施 EORTC QLQ-HL27 将提高 HRQoL 评估的敏感性。预计使用该问卷生成的高质量数据将有助于 HL 环境中的临床决策。
